Skip to main content
Erschienen in: Herz 1/2020

16.07.2019 | Original articles

Deactivation of cardiovascular implantable electronic devices in patients nearing end of life

Reality or only recommendation?

verfasst von: T. Tischer, MD, A. Bebersdorf, C. Albrecht, J. Manhart, MD, A. Büttner, MD, A. Öner, MD, E. Safak, MD, H. Ince, MD, J. Ortak, MD, E. Caglayan, MD

Erschienen in: Herz | Sonderheft 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Current guidelines recommend considering deactivation of cardiac implantable electronic devices (CIEDs) in patients nearing death. We evaluated the implementation of this recommendation in unselected deceased individuals with CIEDs.

Methods

Over a 7-month period in 2016, all deceased persons taken to the Rostock crematorium were prospectively screened for CIEDs and these were interrogated in situ. Pacing rate, pacing mode, and lead output were documented as well as patient data including location and time of death. In implantable cardioverter-defibrillators (ICDs), tachycardia therapy adjustment and occurrence of shocks 24 h prior to death were also recorded.

Results

We examined 2297 subjects, of whom 154 (6.7%) had CIEDs. Of these subjects, 125 (100%) pacemakers (PMs) and 27 (96.4%) ICDs were eligible for analysis. Death in persons with ICDs occurred most frequently in hospital (55.6%), while this was less frequently the case for individuals with PMs (43.2%). Furthermore, 33.3% of subjects with ICDs and 18.5% with PMs died in palliative care units (PCU). Shock therapies were switched off in three (60%) individuals with ICDs who died in the PCU, whereas antibradycardia therapy was not withdrawn in any PM patient in the PCU. Therapy withdrawal occurred in two patients with PMs (1.3%) who died in hospital. Patients with PMs had high ventricular pacing rates at the last interrogation (69 ± 36.0%) and often suffered atrioventricular block (39.2%). Six (25%) of the 24 active ICDs presented shocks near the time of death.

Conclusion

Many CIED patients died in hospital; nonetheless, in practice, CIED deactivation near death is rarely performed and might be less feasible in subjects with PMs. However, there is still a need to consider deactivation, especially in individuals with ICDs, as one fourth of them received at least one shock within 24 h prior to death.
Literatur
2.
Zurück zum Zitat The AVID Investigators (1999) Causes of death in the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol 34(5):1552–1559CrossRef The AVID Investigators (1999) Causes of death in the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol 34(5):1552–1559CrossRef
3.
Zurück zum Zitat Michaelsson M, Jonzon A, Riesenfeld T (1995) Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation 92(3):442–449CrossRef Michaelsson M, Jonzon A, Riesenfeld T (1995) Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation 92(3):442–449CrossRef
4.
Zurück zum Zitat Raatikainen MJP, Arnar DO, Merkely B et al (2017) A decade of information on the use of cardiac Implantable electronic devices and Interventional electrophysiological procedures in the European Society of Cardiology Countries: 2017 report from the European Heart Rhythm Association. Europace 19(Suppl 2):ii1–ii90. https://doi.org/10.1093/europace/eux258CrossRefPubMed Raatikainen MJP, Arnar DO, Merkely B et al (2017) A decade of information on the use of cardiac Implantable electronic devices and Interventional electrophysiological procedures in the European Society of Cardiology Countries: 2017 report from the European Heart Rhythm Association. Europace 19(Suppl 2):ii1–ii90. https://​doi.​org/​10.​1093/​europace/​eux258CrossRefPubMed
5.
Zurück zum Zitat Markewitz A, Bundesfachgruppe Herzschrittmacher (2018) Annual report 2016 of the German pacemaker and defibrillator-register. Part 1: Pacemaker: Working group on pacemaker and defibrillators at the IQTIG-institute for quality assurance and transparency in healthcare. Herzschrittmacherther Elektrophysiol. https://doi.org/10.1007/s00399-018-0603-xCrossRefPubMed Markewitz A, Bundesfachgruppe Herzschrittmacher (2018) Annual report 2016 of the German pacemaker and defibrillator-register. Part 1: Pacemaker: Working group on pacemaker and defibrillators at the IQTIG-institute for quality assurance and transparency in healthcare. Herzschrittmacherther Elektrophysiol. https://​doi.​org/​10.​1007/​s00399-018-0603-xCrossRefPubMed
6.
Zurück zum Zitat Markewitz A, Bundesfachgruppe Herzschrittmacher (2018) Annual report 2016 of the German pacemaker and defibrillator-register. Part 2: Implantable cardioverter defibrillators (ICD): Working group on pacemaker and defibrillators at the at the IQTIG-institute for quality assurance and transparency in healthcare. Herzschrittmacherther Elektrophysiol. https://doi.org/10.1007/s00399-018-0604-9CrossRefPubMed Markewitz A, Bundesfachgruppe Herzschrittmacher (2018) Annual report 2016 of the German pacemaker and defibrillator-register. Part 2: Implantable cardioverter defibrillators (ICD): Working group on pacemaker and defibrillators at the at the IQTIG-institute for quality assurance and transparency in healthcare. Herzschrittmacherther Elektrophysiol. https://​doi.​org/​10.​1007/​s00399-018-0604-9CrossRefPubMed
22.
Zurück zum Zitat Pasalic D, Gazelka HM, Topazian RJ et al (2016) Palliative Care Consultation and Associated End-of-Life Care After Pacemaker or Implantable Cardioverter-Defibrillator Deactivation. Am J Hosp Palliat Care 33(10):966–971CrossRef Pasalic D, Gazelka HM, Topazian RJ et al (2016) Palliative Care Consultation and Associated End-of-Life Care After Pacemaker or Implantable Cardioverter-Defibrillator Deactivation. Am J Hosp Palliat Care 33(10):966–971CrossRef
28.
Zurück zum Zitat Kay GN, Bittner GT (2009) Should implantable cardioverter-defibrillators and permanent pacemakers in patients with terminal illness be deactivated? Deactivating implantable cardioverter-defibrillators and permanent pacemakers in patients with terminal illness. An ethical distinction. Circ Arrhythm Electrophysiol 2(3):336–339. https://doi.org/10.1161/CIRCEP.108.821975CrossRefPubMed Kay GN, Bittner GT (2009) Should implantable cardioverter-defibrillators and permanent pacemakers in patients with terminal illness be deactivated? Deactivating implantable cardioverter-defibrillators and permanent pacemakers in patients with terminal illness. An ethical distinction. Circ Arrhythm Electrophysiol 2(3):336–339. https://​doi.​org/​10.​1161/​CIRCEP.​108.​821975CrossRefPubMed
Metadaten
Titel
Deactivation of cardiovascular implantable electronic devices in patients nearing end of life
Reality or only recommendation?
verfasst von
T. Tischer, MD
A. Bebersdorf
C. Albrecht
J. Manhart, MD
A. Büttner, MD
A. Öner, MD
E. Safak, MD
H. Ince, MD
J. Ortak, MD
E. Caglayan, MD
Publikationsdatum
16.07.2019
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe Sonderheft 1/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-019-4836-1

Weitere Artikel der Sonderheft 1/2020

Herz 1/2020 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.